RT Journal Article
SR Electronic
T1 Poliovirus Vaccination Induces a Humoral Immune Response that Cross Reacts with SARS-CoV-2
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.06.19.21257191
DO 10.1101/2021.06.19.21257191
A1 Brittany A. Comunale
A1 Lilly Engineer
A1 Yong Jiang
A1 John C. Andrews
A1 Qianna Liu
A1 Lyuqing Ji
A1 James T. Yurkovich
A1 Roderick A. Comunale
A1 Qiyi Xie
YR 2021
UL http://medrxiv.org/content/early/2021/06/21/2021.06.19.21257191.abstract
AB Background Millions have been exposed to SARS-CoV-2, but the severity of resultant infections has varied among adults and children, with adults presenting more serious symptomatic cases. Children may possess an immunity that adults lack, possibly from childhood vaccinations. This retrospective study suggests immunization against the poliovirus may provide an immunity to SARS-CoV-2.Methods Publicly available data were analyzed for possible correlations between national median ages and epidemiological outbreak patterns across 100 countries. Sera from 204 adults and children, who were immunized with the poliovirus vaccine, were analyzed using an enzyme-linked immunosorbent assay. The effects of polio-immune serum on SARS-CoV-2-induced cytopathology in cell culture were then evaluated.Results Analyses of median population age demonstrated a positive correlation between median age and SARS-CoV-2 prevalence and death rates. Countries with effective poliovirus immunization protocols and younger populations have fewer and less pathogenic cases of COVID-19. Antibodies to poliovirus and SARS-CoV-2 were found in pediatric sera and in sera from adults recently immunized with polio. Western blot demonstrated antibodies recognized the RNA-dependent-RNA-polymerase (RdRp) of either virus. Sera from polio-immunized individuals inhibited SARS-CoV-2 infection of Vero cell cultures. These results suggest the anti-D3-pol-antibody, induced by poliovirus vaccination, may provide a similar degree of protection from SARS-CoV-2 to adults as to children.Conclusions Poliovirus vaccination induces an adaptive humoral immune response. Antibodies created by poliovirus vaccination bind the RdRp protein of both poliovirus and SARS-CoV-2, thereby preventing SARS-CoV-2 infection. These findings suggest proteins other than “spike” proteins may be suitable targets for immunity and vaccine development.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: BC did not receive any personal fees from E-Mo Biology, Inc. while writing this manuscript, though is pending negotiations for future interests. YJ reports personal fees from GeneScan Diagnostics, LLC. JA and RAC report personal fees from E-Mo Biology, Inc. QX holds an executive position in and reports personal fees from E-Mo Biology, Inc. E-Mo Biology, Inc. has a patent pending. The remaining authors declare that they have no conflicts of interest.Funding StatementThis retrospective study was fully funded by a private source in Southern California. Funders provided finances only and had no involvement in the research activities (project initiation, study design, data collection, analysis, interpretation, results, and inference). All authors had full access to the full data in the study and accept responsibility to submit for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB approval was obtained from BioMed IRB, and samples were purchased from Discovery Life Sciences (Huntsville, AL) in accord with the approved IRB protocol Alabama Biobank Research Trial 001 V3 (ABRT 001-V3)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAuthors can confirm that all relevant data are included in the article.